Resbiotic: Osteobiotic ResO targets joint health through the gut
12 Feb 2026 | Resbiotic
Kara Siedman, senior director of partnerships at Resbiotic, introduces the osteobiotic ResO, a postbiotic-based ingredient designed to support gut health, immunity, and joint mobility. She explains how it differs from traditional glucosamine or collagen supplements, highlights the role the RSB11 postbiotic plays in the formula, shares clinical evidence for mobility benefits, and outlines Resbiotic’s long-term vision for gut-based health solutions.
Hi, this is Benjamin Ferreir for Nutrition Insight, and today I'm speaking with Kara Seidman, who's a registered dietitian and also the senior director of partnerships at Res Biotic.
And today, she's speaking to us about the scientific benefits of the newly launched osteobiotic RESO, which is the company's new ingredient that blends a postbiotic with clinically studied actives to boost gut health, immunity and mobility.
So thank you so much for joining us and just diving right in.
Let's introduce your new ingredient and can you tell us a bit about how this osteobiotic differs from the glucosamine or collagen supplements that currently dominate the joint health space with your gut forward approach?
Yeah, no, this is really exciting because there really isn't anything out there that's like this, that is really harnessing the power of the microbiome.
Most of the supplements out there that are targeting musculoskeletal health, it's really more of this downstream support.
So once discomfort's present, then we're targeting locally what's going on, and this is taking a stronger approach, a more foundational approach that's influenced by our microbiome and these gut immune pathways that drive inflammation to systems beyond.
So, by using our ingredients in this finished product, we're targeting what we call the gut bone joint access.
This is what's helping to regulate inflammatory balance, tissue remodeling, and nutrients that are really promoting not just changes in our, our symptoms, but foundationally supporting those pathways involved.
And was there any reasoning for using a postbiotic for this formula instead of a conventional live probiotic?
Yeah, so our RSB 11 is our patented postbiotic.
Postbiotics are a really exciting area in microbiome therapeutics.
They offer very specific targeted benefits without the need to be alive, and that's the difference between a postbiotic and a live probiotic.
So, this is a heat-treated L.
Plantarum strain.
And we selected it, it's our patented strain that we've actually done internal studies, internal R&D to intimately, to intricately actually understand the mechanism and the benefits around it.
And what we've studied is that we're specifically targeting these gut immune pathways to improve these unhealthy inflammatory responses that can drive inflammation to the bones and to the joints.
And so, it's a really exciting opportunity to offer a patented strain that we've actually studied to truly understand those mechanisms.
Involved.
I'll also add that postbiotics offer greater stability than live probiotics.
It removes any of the manufacturing, the need for survival, this idea of colonization.
And so instead, you're really just getting those targeted selective benefits, which is really exciting when it comes to microbiometherapeutics.
And speaking of clinical data, can you share some findings that prove that Reso improves joint mobility in human subjects?
So, we don't have our completed human outcome data yet.
And so, what's exciting is that that clinical trial, that human clinical trial is underway.
But that said, you know, we believe the fact that we're even running a clinical trial on a finished product formulation.
Is really what we stand for at RSbiotic.
We've done, extensive, very, specialized internal in vitro preclinical studies to show not just the individual impact of the postbiotic, the RSB 11 that we're using, combined with those specific bioactives, the targeted, Herbs and vitamins that we've added into it, as as on the finished product that we're even, that we're getting an even greater improved benefit on the gut bone joint access.
And so, our goal is obviously to be able to translate the exact mechanisms involved into these, you know, clinically meaningful human validated support.
And that's why we're really excited that our human clinical trial is underway.
Since many traditional products only focus on blocking pain, how does Rezo ensure that it's providing long term structural support for connective tissue?
Yeah, I love this question because I think it's such an exciting area that when we feel pain, we jump to obviously traditional supplements or even over the counter medications that, like you said, really target blocking pain, but rezo is really working at a foundational impact of what drives or contributes to ongoing pain in the body, and that is this gut immune connection or this gut immune signaling that influences inflammation and inflammatory responses throughout the body.
So, we're not only providing nutrients that can support connective tissue, bone metabolism, bone turnover, it's the combination of targeting the gut and modulating the microbiome with these bioactives that's supporting not just what often is the driver behind inflammation and, and pain and mobility, but really improving tissue integrity over time, not just providing temporary relief.
And we know that your company pioneered the gut-lung access in your flagship product, RES-B.
What does this move into joint health further tell us about your company's long term vision for a new product development?
Yeah, and so this is really our foundation of what we call the gut X axis, and our founder always says, you know, X being sort of anything when it comes to, math and algebra.
And this is really a part of the larger understanding around the microbiome space and how the microbiome impacts systems beyond just our gut and digestive tract.
And so, we're really pioneering this space in using our patented strains to understand the targeted and very specific or precision.
Benefits in impacting not just the gut, but getting this system-specific precision.
And so, I think this is an exciting area.
We know more about the gut bone joint access.
There really isn't a lot of, options out there that are, where you're getting this dual effect in not just supporting the environment in the GI tract, but then getting these very specific targeted impacts to improve these symptoms like joint pain, like mobility, flexibility, etc.
